Cargando…

Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis

It is not well determined whether primary tumor resection is associated with better outcomes in metastatic colorectal cancer (mCRC) patients treated with bevacizumab. In this meta-analysis, we aimed to assess the prognostic role of primary tumor resection in mCRC treated with bevacizumab. Electronic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Dedong, Zheng, Yongfa, Xu, Huilin, Ge, Wei, Xu, Ximing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937309/ https://www.ncbi.nlm.nih.gov/pubmed/31889159 http://dx.doi.org/10.1038/s41598-019-56528-2

Ejemplares similares

The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis
por: Zhao, Nan, et al.
Publicado: (2022)

Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
por: Ghiringhelli, Francois, et al.
Publicado: (2014)

The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: dedong, Cao, et al.
Publicado: (2016)

The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
por: Xu, Huilin, et al.
Publicado: (2020)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
por: Su, Yi-Chia, et al.
Publicado: (2022)

Asymptomatic Primary Tumor Resection in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Shu, Yefei, et al.
Publicado: (2022)

Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
por: Xu, Huilin, et al.
Publicado: (2023)

Efficacy of Primary Tumor Resection in Metastatic Colorectal Cancer
por: Huang, Yong, et al.
Publicado: (2020)

Influence of primary tumor location and resection on survival in metastatic colorectal cancer
por: Tharin, Zoé, et al.
Publicado: (2020)

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
por: Cao, Dedong, et al.
Publicado: (2018)

The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials
por: Ge, Wei, et al.
Publicado: (2018)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
por: You, Xia-Hong, et al.
Publicado: (2019)

The extracellular vesicles secreted by lung cancer cells in radiation therapy promote endothelial cell angiogenesis by transferring miR-23a
por: Zheng, Yongfa, et al.
Publicado: (2017)

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
por: Ilic, Irena, et al.
Publicado: (2016)

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma
por: Liu, Xiaohong, et al.
Publicado: (2022)

Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?
por: Ergun, Yakup, et al.
Publicado: (2020)

Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer
por: Xu, Jing, et al.
Publicado: (2019)

Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer
por: Yang, Yi, et al.
Publicado: (2020)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
por: Amit, Limor, et al.
Publicado: (2013)

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection
por: Osterlund, Pia, et al.
Publicado: (2014)

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies
por: Fanotto, Valentina, et al.
Publicado: (2023)

Correction: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
por: Amit, Limor, et al.
Publicado: (2013)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
por: Cao, De-Dong, et al.
Publicado: (2017)

Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients
por: He, Wen-Zhuo, et al.
Publicado: (2017)

Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis
por: Xu, Hong, et al.
Publicado: (2015)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness
por: Chibani, Hind, et al.
Publicado: (2022)

The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy
por: Yeom, Seung-Seop, et al.
Publicado: (2020)

Primary tumor resection benefited the survival of patients with distant metastatic gastric cancer
por: Gao, Yan, et al.
Publicado: (2021)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Palliative resection of a primary tumor in patients with unresectable colorectal cancer: could resection type improve survival?
por: Jang, Hyun Seok, et al.
Publicado: (2016)

Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis
por: Zhang, Chun-Jing, et al.
Publicado: (2018)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
por: Cai, Jun, et al.
Publicado: (2013)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8qj6t5ofi5sq2edn7mk0f47p7